Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shell cuts Q1 LNG output forecast on Australia issues

(Sharecast News) - Energy giant Shell on Monday cut its first-quarter liquefied natural gas (LNG) production outlook, citing citing cyclones and unplanned maintenance in Australia. The company said it now expected LNG output of 6.4 million - 6.8 million metric tonnes, down from a previous forecast of 6.6 million to 7.2 million. It added that gas division trading results would be in line with the previous quarter.

Shell also said it expects to book a $100m exploration well write-off. The company is looking to strip out a cumulative $5bn to $7bn a year by the end of 2028.

"In its usual teaser ahead of quarterly results Shell presented a mixed picture of performance as the shares continued to crater thanks to the impact of US tariffs on energy prices," said AJ Bell investment director Russ Mould.

"One of Shell's key strengths is its dominant position in natural gas, so it will disappoint shareholders that this part of the business is not firing on all cylinders."

"Under chief executive Wael Sawan the company has been looking to up its game to catch up with its US peers and Shell has done better at keeping pace than its UK-listed peer BP."

"However, the danger is that anything investors take from today's update and Shell's previous progress could be overtaken by events by the time it puts its first-quarter numbers out in full at the beginning of May. If oil and gas prices remain under pressure then efforts to improve financial performance could prove as forlorn as trying to make a souffle on a camping stove in the middle of a storm."

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.